Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Metrics to compare | ZBIO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipZBIOPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.8x | −0.6x | −0.5x | |
PEG Ratio | −0.04 | 0.00 | 0.00 | |
Price/Book | 1.6x | 1.8x | 2.6x | |
Price / LTM Sales | 30.7x | 10.5x | 3.0x | |
Upside (Analyst Target) | 217.9% | 55.8% | 54.7% | |
Fair Value Upside | Unlock | −2.0% | 8.4% | Unlock |